research
A RAS Inhibitor Extended Survival in an Eligible Pancreatic-Cancer Trial Group
An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.
Summary
An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.
A Johns Hopkins Kimmel Cancer Center overview says a trial of the once-daily RAS(ON) inhibitor daraxonrasib reported median survival of 13.2 months, versus 6.7 months in the comparison context, for eligible patients with metastatic pancreatic ductal adenocarcinoma after chemotherapy stopped working. The drug is investigational, and the result does not apply to every pancreatic-cancer patient.
Why it matters
An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.
Limits and context
- The drug is investigational, and the result does not apply to every pancreatic-cancer patient.
Key claims
An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.
Qualification: The drug is investigational, and the result does not apply to every pancreatic-cancer patient.
Evidence: source-2026-08-01-019
Sources
- Johns Hopkins Kimmel Cancer Center via Newswise: Daraxonrasib trial overviewJohns Hopkins Kimmel Cancer Center via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.